In canine congestive heart failure protocols documented in ACVIM 2019 consensus guidelines, thiazide diuretics occupy a defined adjunctive position when loop diuretic monotherapy fails to control pulmonary oedema. Dihydrochlorothiazide, referred to as hydrochlorothiazide in USP and Ph. Eur. monographs, is combined with furosemide to achieve sequential nephron blockade. Furosemide inhibits the Na⁺-K⁺-2Cl⁻ cotransporter in the thick ascending limb of the loop of Henle. Hydrochlorothiazide inhibits the Na⁺-Cl⁻ cotransporter in the distal convoluted tubule. The combined effect overcomes diuretic resistance encountered at terminal dosing of furosemide alone. Oral tablet strengths of 12.5 mg, 25 mg, and 50 mg support the canine labelled dosing range of 2–4 mg/kg administered at 12-hour intervals. Additional dosing flexibility is achieved through scored tablet configurations permitting half-tablet increments for small-breed dogs.

Tablet manufacture from veterinary-grade API requires specific attention to crystal morphology and particle size distribution. Hydrochlorothiazide forms needle-like crystals with poor compressibility and low flowability. Wet granulation with a binder solution improves granule density and tablet hardness. A typical wet granulation process uses purified water or a 3% w/w povidone K30 binder solution. Granulation endpoint is reached at 5–8 minutes of kneading time in a high-shear granulator at impeller speed 150–200 rpm. Dried granules are milled through a 0.8 mm screen. Lubrication with magnesium stearate at 0.5–1.0% w/w is added prior to compression. The rotary press is operated at compression force 5–12 kN to achieve target hardness 5–8 kp. Disintegration testing per USP <701> requires complete disintegration within 15 minutes in purified water at 37 ± 2°C. Content uniformity per USP <905> assesses individual tablet assay values within 85.0–115.0% of label claim. Batch-to-batch variance in particle size D90 exceeding 100 μm typically degrades content uniformity on rotary tablet presses running above 60 rpm.

Serum electrolyte monitoring is mandatory during thiazide therapy in dogs. Hypokalaemia at serum potassium below 3.5 mEq/L requires supplementation with potassium gluconate or potassium citrate at 0.5–1.0 mEq/kg every 12 hours. Concurrent administration with ACE inhibitors such as enalapril or benazepril elevates the risk of azotaemia. Serum creatinine and blood urea nitrogen are measured at 7 days, 30 days, and every 90 days thereafter. Published veterinary cardiology literature confirms the adjunctive role of thiazides in refractory cases where furosemide dose escalation beyond 8 mg/kg/day yields diminishing diuretic response.

Why does suspension pH govern reconstituted stability in feline dose forms?

Feline dosing for hypertension and congestive heart failure ranges from 1 mg/kg to 2 mg/kg administered every 12 to 24 hours. Unit doses below 5 mg require suspension vehicles to permit accurate volumetric administration from a graduated oral syringe. Compounded oral suspensions at 5 mg/mL or 2.5 mg/mL are prepared from bulk veterinary-grade API. Hydrochlorothiazide aqueous solubility of approximately 0.72 mg/mL at 25°C classifies the API as practically insoluble in water per USP solubility criteria. Suspension formulation does not involve true dissolution of the entire dose. A fraction of the drug remains undissolved and requires uniform redispersion prior to each administration.

Vehicle pH exerts the dominant influence on both chemical stability and physical suspension behaviour. Suspensions prepared in a 1:1 mixture of Ora-Plus and Ora-Sweet, buffered to pH 4.5–5.5, demonstrate acceptable sedimentation volume F in the range 0.80–0.90 one hour after shaking. The sedimentation volume F is defined as the ratio of sediment height to total suspension height after a defined standing period. Below pH 4.0, increased protonation of the sulfonamide nitrogen accelerates particle aggregation. Above pH 6.5, hydrolytic degradation of the benzothiadiazine ring proceeds at a measurable rate under accelerated storage at 40°C and 75% relative humidity. Compounded aqueous suspensions without preservative are assigned a beyond-use date of 14 days under refrigerated storage per USP <795>. Preserved formulations containing methylparaben 0.1% w/w and propylparaben 0.02% w/w may be assigned a beyond-use date of up to 35 days under refrigerated storage. Particle size of dispersed API is maintained below D90 50 μm through micronisation. Sieve retention on a 100-mesh screen (150 μm aperture) is controlled to avoid dose non-uniformity from settling.

A stability assessment matrix for compounded hydrochlorothiazide suspensions is summarised in Table 1.

When recurrent calcium oxalate urolithiasis is confirmed by quantitative stone analysis, thiazide administration at 2 mg/kg every 12 hours reduces fractional urinary calcium excretion in canine patients. The diuretic action at the distal convoluted tubule inhibits the Na⁺-Cl⁻ cotransporter and secondarily reduces calcium reabsorption, producing a documented reduction in urinary calcium output relative to baseline in treated patients. Capsule strengths of 5 mg, 10 mg, and 12.5 mg support precise dose adjustment for canine patients weighing 2–20 kg and feline patients at 1 mg/kg every 12 hours. Hydrochlorothiazide therapy for calcium oxalate prevention is initiated only after complete urolith removal and confirmation of urinary supersaturation risk. Published case series in veterinary nephrology literature report reduced recurrence intervals for calcium oxalate uroliths when thiazide therapy is combined with potassium citrate urinary alkalinisation and a canned high-moisture diet formulated to maintain urine specific gravity below 1.020.

Capsule compounding from bulk veterinary-grade API requires geometric dilution to ensure homogeneous distribution in the final preparation. Lactose monohydrate or microcrystalline cellulose at 50–200 mg per capsule serves as diluent. Trituration in a porcelain mortar with progressive doubling of diluent volume is performed until the target strength is reached. Humidity in the compounding area is maintained below 40% relative humidity to prevent moisture sorption by the API. Hard gelatin or hypromellose capsules are filled using semi-automatic capsule machines with tamping pins set at 50–60% stroke. Content uniformity per USP <905> requires individual capsule assay values within 85.0–115.0% of label claim and a relative standard deviation of not more than 6.0%. Batch records document the API lot number, assay certificate at 98.0–102.0% on dried basis, and residual solvent profile per USP <467>.

Monitoring protocols after initiation include serum calcium, blood urea nitrogen, serum creatinine, and serum potassium at 2 weeks and every 6 months thereafter. Hypercalcaemia is an exclusion criterion. Concurrent administration with calcium supplements, calcium-based phosphate binders, or vitamin D analogues is contraindicated due to the risk of hypercalcaemia. Thiazide diuretics decrease urinary calcium clearance and may unmask occult hyperparathyroidism. Dose reduction or discontinuation is indicated when serum calcium exceeds the laboratory reference interval or when serum creatinine increases by more than 30% from baseline.

Sterile lyophilisation of a practically insoluble thiazide requires co-solvent tolerance screening

For injectable processing, hydrochlorothiazide aqueous solubility below 1 mg/mL prevents direct dissolution of therapeutic parenteral doses in water for injection. Injectable formulation from bulk API requires either pH adjustment above 9.0 using sodium hydroxide or incorporation of co-solvents such as ethanol, propylene glycol, or polyethylene glycol 300. Alkaline pH accelerates hydrolytic ring opening of the benzothiadiazine nucleus with degradation products measurable by USP-related compound methods at chlorothiazide NMT 0.5% and total impurities NMT 1.0%. Stabilisation under alkaline conditions is therefore confined to brief hold times before lyophilisation. Sterile filtration at 0.22 μm membrane pore size is performed on the pH-adjusted or co-solvent solution. Filter membrane compatibility with alkaline drug solutions requires validation using nylon 66 or polyethersulfone membranes. Flow rate testing per ISO 13408-2 aseptic processing guidance is documented in the batch record.

Lyophilisation cycle parameters for a 25 mg/vial nominal dose involve freezing to −40°C at a ramp rate of 1°C per minute, primary drying at shelf temperature −20°C with chamber pressure 0.1 mbar for 36 hours, and secondary drying at 25°C until final moisture content is below 1.0% w/w. The lyophilised cake is reconstituted with sterile water for injection or 0.9% sodium chloride at the point of use. Reconstitution of the lyophilised cake in normal saline at 25°C yields a stable solution for 24 hours. Direct dissolution of non-lyophilised API in saline results in precipitation and is not performed. Published data for veterinary-specific injectable hydrochlorothiazide is limited to research-scale preparations and emergency use reports. No veterinary injectable product containing hydrochlorothiazide as the sole active is registered in major regulatory markets as of the current revision. Parenteral administration is therefore confined to institutional settings with controlled reconstitution procedures.

Intravenous or intramuscular administration of unformulated bulk API is strictly prohibited. The veterinary-grade API certificate of analysis for injectable processing must additionally include bacterial endotoxin testing per USP <85> with a limit of NMT 2.5 EU/mg and sterility testing per USP <71>. Pyrogen-free processing vessels and terminal sterilisation are not substitutes for validated aseptic technique. Batch rejection occurs when endotoxin levels exceed the limit or when sterility test failures are confirmed at 14 days of incubation.

Equine distal limb oedema powder and granule dose titration

Clinically, published pharmacokinetic data for hydrochlorothiazide administration in equine patients is limited. Therapeutic protocols are derived from extrapolated small-animal and human dose normalisation rather than equine-specific bioavailability studies. Anecdotal clinical use in equine distal limb oedema describes a dosage of 0.5–1 mg/kg administered once daily or every other day in feed. Loop diuretics such as furosemide remain the first-line diuretic choice for equine cardiogenic pulmonary oedema and acute fluid overload. Thiazide use in equine medicine is therefore confined to chronic maintenance therapy where aggressive volume contraction is undesirable. Granulation of bulk API with palatable carriers improves intake consistency. Granules containing 50 mg hydrochlorothiazide per 5 g scoop, blended with a molasses-flavoured dextrose base, permit dose adjustment in 50 mg increments for horses weighing 100–600 kg.

Feed refusal is documented in a subset of horses receiving unflavoured API powder. Granulation with a 10% w/w povidone binder solution and drying at 40°C for 6 hours reduces dusting during feed mixing. Race-day restriction policies prohibit thiazide administration in performance horses due to potential interference with haemodilution markers used in doping control. Hydrochlorothiazide is not approved for use in food-producing animals in the European Union under Regulation (EU) 2019/6 and the United States under 21 CFR 530. Equine patients are classified as non-food animals only when permanent exclusion from the food chain is documented in the medical record.

When bulk API particle size distribution shifts dry powder flow in compounding suites

Because bulk API particle size distribution shifts dry powder flow in compounding suites, veterinary pharmacies must establish incoming lot-specific particle characterisation prior to capsule filling. Laser diffraction per ISO 13320 reports D10, D50, and D90 values on the certificate of analysis. A D90 shift from 50 μm to 150 μm across manufacturer lots produces measurable flow changes in dry powder capsule filling. Needle-like crystal morphology contributes to high angle of repose values above 40°, which classifies the powder as cohesive to very cohesive per USP <1174>. Compounding pharmacies mitigate flow variability by pre-sieving through a 60-mesh screen (250 μm aperture) and incorporating 1–2% w/w colloidal silicon dioxide or 0.5–1% w/w magnesium stearate as glidant. Over-lubrication with magnesium stearate above 2% w/w reduces capsule dissolution by hydrophobising the API surface, a failure observed in dissolution testing at 30 minutes with less than 75% released per USP <711>.

Non-sterile compounding of hydrochlorothiazide capsules and powders is governed by USP <795> with beyond-use date assignment of 180 days for dry formulations stored at controlled room temperature 20–25°C. Each finished preparation is labelled with the beyond-use date, storage conditions, and lot-specific internal control number. The compounding batch record documents the API certificate of analysis including assay at 98.0–102.0% on dried basis, loss on drying NMT 0.5%, residue on ignition NMT 0.1%, chlorothiazide related compound NMT 0.5%, total impurities NMT 1.0%, and residual solvents per USP <467>. Table 2 summarises the release specification checklist for veterinary-grade bulk API used in non-sterile compounding operations.